Clinical trial · Interventional
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia
NCT00233506CI-TRIAL-00025801completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* CpG has the potential to stimulate the immune system * this study will evaluate the safety of CpG given sub-q or IV * purpose is to measure biological changes in CLL cells after receiving CpG
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CpG 7909 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CPG 7909 IV
- description
- Intravenous infusions will be administered with a standard infusion pump beginning at 125 cc/hr through an intravenous catheter (central or peripheral).
- interventionNames
- Drug: CpG 7909
- type
- EXPERIMENTAL
- label
- CPG 7909 SQ
- description
- Subcutaneous injections should be administered in the abdominal wall, upper arm, hip, or anterior thigh. If the volume of injection exceeds 1.5 ml, the volume should be divided into equal injections at a volume less than 1.5 ml and administered in different areas of the body. The maximum dose level on this trial may require 5 - 6 injections at an equal number of sites.
- interventionNames
- Drug: CpG 7909
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of CLL * CLL previously treated * Hemoglobin \>/= 10 * Platelets \>/= 50,000 * Neutrophils \>= 1,000 - Exclusion Criteria: * patients with brain mets * patients with autoimmune disease * patients on corticosteroids or immunosuppressants * patients with uncontrolled intercurrent illness * pregnant women * HIV patients receiving combination anti-retroviral therapy
References
Publications (0)
Data not yet available
No reference posted for this study.